EV Group Strengthens Its European Presence With the Acquisition of Cornelius Polska
Eigenmann & Veronelli Group (“EV Group”), a leading distributor and manufacturer of specialty chemicals and food ingredients, has signed an agreement to acquire the majority shareholding in Cornelius Polska.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122961168/en/
Photographed (left to right): Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Piotr Wasilewski, General Manager, Cornelius Polska Sp. z. o. o.; Cristina Colombo, Chief Financial Officer, EV Group; Dr Neville Prior, Group Chairman, Cornelius Group plc; Gabriele Bonomi, Chief Executive Officer, EV Group
Established in Poland in 2007 and headquartered in Warsaw, Poland, Cornelius Polska is a well‑established distributor of specialty chemicals, serving as a key partner to international suppliers, and a broad and diverse customer base. With operations firmly rooted in Poland, the company is active in the beauty & personal care, food, and several industrial markets.
With a comprehensive premium product portfolio and a highly skilled team of approximately 28 people, Cornelius Polska is recognized for its technical expertise, long‑standing relationships, and strong commercial capabilities. In 2025, the company reported annual revenues of around EUR 16 million.
This acquisition represents a highly strategic step for EV Group, enhancing the Group’s scale and strengthening its presence across Europe. It also unlocks new growth potential and strategic opportunities in the beauty and personal care, food, and industrial markets.
“This is an important milestone in expanding our footprint in Europe,” said Gabriele Bonomi, CEO of EV Group. “Cornelius Polska brings deep local market knowledge, a loyal customer base, and a strong platform for growth across multiple applications, making it a real asset for our partners, teams, and suppliers across Europe. We are also pleased to welcome a highly experienced and skilled team that will add significant value to our organization and ensure continuity in established customer and supplier relationships.”
Dr. Neville Prior, Chairman of the Cornelius Group, said: “Cornelius Polska has been an important part of our organisation for many years, and we are extremely proud of what the team has accomplished. Joining EV Group creates new opportunities for both the business and its people, and I am confident this transition will deliver lasting value for customers and partners.”
The transaction is subject to customary regulatory approvals and closing conditions, and completion is expected in the first quarter of 2026.
EVGROUP
Founded in 1910, Eigenmann & Veronelli Group is an international solutions provider of specialty chemicals and food ingredients. Headquartered in Pero, Italy, EV has a direct presence in Italy, Iberia, Turkey, and the U.A.E. and a commercial reach in more than 45 countries. In 2025, EV generated a consolidated turnover of 340 million euros with more than 350 employees. With over a century of experience, EV is synonymous with effectiveness and efficiency, combining local market knowledge with chemical innovations, and offering a high-quality and diversified portfolio of specialty chemicals and food ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, and comprehensive regulatory know-how for a wide range of industries.
Follow us on LinkedIn
CORNELIUS GROUP
Cornelius Group is an independent manufacturer and distributor of raw materials, ingredients and specialty chemicals for life science, performance chemicals and ocular sector operating in UK, Europe, Asia and USA. The core business values: We Lead, We Care, We Deliver are at the heart of the vision, strategy and everyday thinking to deliver differentiated outcomes for both customers and business partners. Cornelius has an active membership to the UN Global Compact, ISO accredited for Quality Management (9001:2015), Environmental Management Systems (14001:2015) and Occupational Health and Safety Management (45001).
Follow us on LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20260122961168/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting konsoliderer sit udbud inden for digital transformation med tilføjelsen af Internet & Idee22.1.2026 14:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Internet & Idee, et italiensk digitalt konsulentbureau, og styrker dermed sin evne til at levere integrerede, teknologidrevne løsninger. Internet & Idee blev stiftet i 1998 og specialiserer sig i digital strategi, softwareudvikling, test og kvalitetssikring, e-handel og mobile løsninger. Virksomheden opererer inden for to kerneområder: It-konsulentydelser og egne SaaS-produkter, herunder værktøjer til kreditstyring og cybersikkerhed. Med dyb ekspertise inden for bankvæsen, forsikring, kreditstyring og logistik for e-handel kombinerer Internet & Idee brancheindsigt med teknisk innovation med henblik på at drive forretningsresultater. "Dette samarbejde giver os mulighed for at anvende vores digitale ekspertise og branchekendskab i større skala," udtaler Carlo Stumpo, administrerende direktør for Internet & Idee. "Sammen med Andersen Consulting kan vi levere mere målrettede og effektive løsninger til kunder, der står over for komplekse ud
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release
Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax
ExaGrid Announces All Flash/SSD Tiered Backup Storage Solution22.1.2026 14:00:00 CET | Press release
ExaGrid’s new solution offers the fastest, most scalable, and most secure backups in the industry ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it is shipping an All Flash/SSD backup storage solution with a unique front-end Landing Zone and non-network-facing Repository Tier (tiered air gap) that stores all backup retention using advanced data deduplication. The new SSD appliances ship with ExaGrid software version 8. ExaGrid’s unique Landing Zone and scale-out architecture allow for significantly faster backups and restores, as well as scalability as data grows, versus other SSD products such as Dell Data Domain inline deduplication appliances with SSD or straight SSD from Pure Storage. Due to three years of software work and the extremely fast performance of SSD, ExaGrid’s
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis22.1.2026 14:00:00 CET | Press release
New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers. Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by provi
AMGTA Announces EOS as New Principal Member and Appoints Björn Hannappel to Board of Directors22.1.2026 13:59:00 CET | Press release
The Additive Manufacturer Green Trade Association (AMGTA) today announced that EOS has elevated its longstanding participation in the association to Principal Member. As part of this expanded leadership role, Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121601881/en/ Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. Principal Membership represents AMGTA’s highest level of engagement and is reserved for organizations demonstrating sustained leadership, strategic alignment, and a commitment to advancing sustainable and resilient manufacturing practices globally. As a Principal Member, EOS will take on an expanded role in shaping AMGTA’s strategic direction, governance, and industry collaboration initiatives. EOS is a world-leading technology supplier in the field of commercial 3D printing of meta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom